Theocharidou Eleni, Dhar Ameet, Patch David
The Royal Free Sheila Sherlock Liver Centre, Royal Free Hospital, Royal Free Hampstead NHS Trust, University College London, London, UK.
Section of Hepatology, Department of Medicine, St Mary's Hospital, Imperial College London, London, UK.
Gastroenterol Res Pract. 2017;2017:8270310. doi: 10.1155/2017/8270310. Epub 2017 May 11.
Gastrointestinal motility is impaired in a substantial proportion of patients with cirrhosis. Cirrhosis-related autonomic neuropathy, increased nitric oxide production, and gut hormonal changes have been implicated. Oesophageal dysmotility has been associated with increased frequency of abnormal gastro-oesophageal reflux. Impaired gastric emptying and accommodation may result in early satiety and may have an impact on the nutritional status of these patients. Small intestinal dysmotility might be implicated in small intestinal bacterial overgrowth and increased bacterial translocation. The latter has been implicated in the pathophysiology of hepatic encephalopathy and spontaneous bacterial peritonitis. Enhanced colonic motility is usually associated with the use of lactulose. Pharmacological interventions aiming to alter gastrointestinal motility in cirrhosis could potentially have a beneficial effect reducing the risk of hepatic decompensation and improving prognosis.
在相当一部分肝硬化患者中,胃肠动力受损。肝硬化相关的自主神经病变、一氧化氮生成增加以及肠道激素变化都与之有关。食管动力障碍与胃食管反流异常频率增加有关。胃排空和容受功能受损可能导致早饱,并可能影响这些患者的营养状况。小肠动力障碍可能与小肠细菌过度生长和细菌移位增加有关。后者与肝性脑病和自发性细菌性腹膜炎的病理生理有关。结肠动力增强通常与乳果糖的使用有关。旨在改变肝硬化患者胃肠动力的药物干预可能会产生有益效果,降低肝失代偿风险并改善预后。